Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Essler

Showing results (121-130 of 208) with videos related to

Pageof 21
Sort By:
Oncotarget|September 15, 2017
Radioligand therapy of metastatic prostate cancer using <sup>177</sup>Lu-PSMA-617 after radiation exposure to <sup>223</sup>Ra-dichlorideHojjat Ahmadzadehfar, Stefanie Zimbelmann, Anna Yordanova, et al.
The International Journal of Cardiovascular Imaging|July 10, 2012
Quantitative assessment of glucose metabolism in the vessel wall of abdominal aortic aneurysms: correlation with histology and role of partial volume correctionChristian Reeps, Ralph A Bundschuh, Jaroslav Pellisek, et al.
Nuklearmedizin. Nuclear Medicine|June 30, 2025
Psycho-Oncological Screening Identifies High-Risk Subgroups Among Neuroendocrine Tumor Patients Undergoing PRRT with [177Lu]Lu-DOTATATE: Implications for SurvivalBarbara Kreppel, Hannah M Jochims, Milka Marinova, et al.
The Prostate|July 21, 2022
Any decline in prostate-specific antigen levels identifies survivors scheduled for prostate-specific membrane antigen-directed radioligand therapyPhilipp E Hartrampf, Franz-Xaver Weinzierl, Anna Katharina Seitz, et al.
Oncotarget|September 15, 2017
Uptake of PSMA-ligands in normal tissues is dependent on tumor load in patients with prostate cancerFlorian C Gaertner, Khalil Halabi, Hojjat Ahmadzadehfar, et al.
Oncotarget|December 22, 2017
Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [<sup>177</sup>Lu]Lu-PSMA-617 radioligand therapyHojjat Ahmadzadehfar, Stephan Schlolaut, Rolf Fimmers, et al.
The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR), [And] Section of the Society Of|May 22, 2014
Significance of multiple nodal basin drainage in patients with truncal melanomaHojjat Ahmadzadehfar, Torsten Hinz, Anja Wierzbicki, et al.
European Radiology|November 13, 2015
Incidence and risk factors of early arterial blood flow stasis during first radioembolization of primary and secondary liver malignancy using resin microspheres: an initial single-center analysisClaus Christian Pieper, Winfried A Willinek, Daniel Thomas, et al.
Oncotarget|July 11, 2019
Prostate-specific membrane antigen expression in hepatocellular carcinoma: potential use for prognosis and diagnostic imagingYuri Tolkach, Diane Goltz, Anika Kremer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 29, 2018
The Role of Adding Somatostatin Analogues to Peptide Receptor Radionuclide Therapy as a Combination and Maintenance TherapyAnna Yordanova, Marcel M Wicharz, Karin Mayer, et al.
Pageof 21

Showing results (121-130 of 208) with videos related to

Sort By:
Pageof 21
Oncotarget|September 15, 2017
Radioligand therapy of metastatic prostate cancer using <sup>177</sup>Lu-PSMA-617 after radiation exposure to <sup>223</sup>Ra-dichlorideHojjat Ahmadzadehfar, Stefanie Zimbelmann, Anna Yordanova, et al.
The International Journal of Cardiovascular Imaging|July 10, 2012
Quantitative assessment of glucose metabolism in the vessel wall of abdominal aortic aneurysms: correlation with histology and role of partial volume correctionChristian Reeps, Ralph A Bundschuh, Jaroslav Pellisek, et al.
Nuklearmedizin. Nuclear Medicine|June 30, 2025
Psycho-Oncological Screening Identifies High-Risk Subgroups Among Neuroendocrine Tumor Patients Undergoing PRRT with [177Lu]Lu-DOTATATE: Implications for SurvivalBarbara Kreppel, Hannah M Jochims, Milka Marinova, et al.
The Prostate|July 21, 2022
Any decline in prostate-specific antigen levels identifies survivors scheduled for prostate-specific membrane antigen-directed radioligand therapyPhilipp E Hartrampf, Franz-Xaver Weinzierl, Anna Katharina Seitz, et al.
Oncotarget|September 15, 2017
Uptake of PSMA-ligands in normal tissues is dependent on tumor load in patients with prostate cancerFlorian C Gaertner, Khalil Halabi, Hojjat Ahmadzadehfar, et al.
Oncotarget|December 22, 2017
Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [<sup>177</sup>Lu]Lu-PSMA-617 radioligand therapyHojjat Ahmadzadehfar, Stephan Schlolaut, Rolf Fimmers, et al.
The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR), [And] Section of the Society Of|May 22, 2014
Significance of multiple nodal basin drainage in patients with truncal melanomaHojjat Ahmadzadehfar, Torsten Hinz, Anja Wierzbicki, et al.
European Radiology|November 13, 2015
Incidence and risk factors of early arterial blood flow stasis during first radioembolization of primary and secondary liver malignancy using resin microspheres: an initial single-center analysisClaus Christian Pieper, Winfried A Willinek, Daniel Thomas, et al.
Oncotarget|July 11, 2019
Prostate-specific membrane antigen expression in hepatocellular carcinoma: potential use for prognosis and diagnostic imagingYuri Tolkach, Diane Goltz, Anika Kremer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 29, 2018
The Role of Adding Somatostatin Analogues to Peptide Receptor Radionuclide Therapy as a Combination and Maintenance TherapyAnna Yordanova, Marcel M Wicharz, Karin Mayer, et al.
Pageof 21